2,2,6-trimethyl-heptan-4-ol | 66256-44-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2,6-trimethyl-heptan-4-ol
• 英文别名: Isobutyl-neopentyl-carbinol；2,2,6-Trimethylheptan-4-ol
• CAS: 66256-44-8
• 化学式: C₁₀H₂₂O
• 分子量: 158.284
• InChiKey: ITTQYDBLGDGLMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2,6-trimethyl-heptan-4-ol 、 1-Alapha-萘异氰酸酯 生成 [1]naphthyl-carbamic acid-(1-isobutyl-3,3-dimethyl-butyl ester)
  参考文献：
  名称：

  Whitmore; Forster, Journal of the American Chemical Society, 1942, vol. 64, p. 2967

  摘要：

  DOI：
• 作为产物：
  描述：

  3,3-二甲基丁酰氯 、 ISOBUTYLMAGNESIUM BROMIDE 在 乙醚 作用下， 生成 2,2,6-trimethyl-heptan-4-ol
  参考文献：
  名称：

  Whitmore; Forster, Journal of the American Chemical Society, 1942, vol. 64, p. 2967

  摘要：

  DOI：

文献信息

• LOW VISCOSITY LOW VOLATILITY LUBRICATING OIL BASE STOCKS AND PROCESSES FOR PREPARING SAME
  申请人：ExxonMobil Research and Engineering Company

  公开号：US20170137734A1

  公开（公告）日：2017-05-18

  A composition that includes one or more compounds represented by the formula R 1 —O—R 2 wherein R 1 is a substituted or unsubstituted aryl or polyaryl group having from about 4 to about 40 carbon atoms, and R 2 is a substituted or unsubstituted, linear or branched, alkyl group having from about 4 to about 40 carbon atoms. The composition has a viscosity (Kv 100 ) from about 1 to about 10 cSt at 100° C. as determined by ASTM D-445, a viscosity index (VI) from about −100 to about 300 as determined by ASTM D-2270, and a Noack volatility of no greater than 50 percent as determined by ASTM D-5800. The disclosure also relates to a process for producing the composition, a lubricating oil base stock and lubricating oil containing the composition, and a method of reducing boundary friction and improving dispersancy of polar additives of a lubricating oil by using as the lubricating oil a formulated oil containing the composition.

  一种包括一个或多个化合物的组合物，其表示为R1—O—R2，其中R1是具有约4至约40个碳原子的取代或未取代芳基或多芳基基团，R2是具有约4至约40个碳原子的取代或未取代、线性或支链烷基基团。该组合物在100°C下通过ASTM D-445确定的粘度（Kv100）约为1至约10厘斯特，通过ASTM D-2270确定的粘度指数（VI）约为-100至约300，通过ASTM D-5800确定的Noack挥发度不大于50％。该公开还涉及一种生产该组合物的方法，含有该组合物的润滑油基础油和润滑油，以及通过使用含有该组合物的配制油作为润滑油来减少边界摩擦并改善润滑油中极性添加剂的分散性的方法。
• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。
• Nitrogen-Containing Aromatic Derivatives
  申请人：Funahashi Yasuhiro

  公开号：US20100197911A1

  公开（公告）日：2010-08-05

  Compounds represented by the following general formula: [wherein A g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X g is —O—, —S—, etc.; Y g is an optionally substituted C 6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T g1 is a group represented by the following general formula: (wherein E g is a single bond or —N(R g2 )—, R g1 and R g2 each independently represent a hydrogen atom, an optionally substituted C 1-6 alkyl group, etc. and Z g represents a C 1-8 alkyl group, a C 3-8 alicyclic hydrocarbon group, a C 6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.

  以下是由下列通式表示的化合物：[其中Ag是可选取代的5-至14-成员杂环基团等；Xg是-O-，-S-等；Yg是可选取代的C6-14芳基团，可选取代的5-至14-成员杂环基团等；Tg1是由下列通式表示的基团：（其中Eg是单键或-N（Rg2）-，Rg1和Rg2各自独立地表示氢原子，可选取代的C1-6烷基团等；Zg表示C1-8烷基团，C3-8萜环碳氢基团，C6-14芳基团等）]，其盐或上述化合物的水合物。
• INHIBITORS OF HUMAN 12/15-LIPOXYGENASE
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20160168137A1

  公开（公告）日：2016-06-16

  A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.

  一项系统筛查已经发现了一类化合物，具有对12/15-脂氧化酶抑制作用。因此，本发明涉及使用这些化合物来抑制12/15-脂氧化酶并治疗涉及12/15-脂氧化酶的疾病。示例疾病包括但不限于中风、室旁白质脑病、心脏骤停复苏、动脉粥样硬化、帕金森病、阿尔茨海默病和乳腺癌。
• US9095142B2
  申请人：——

  公开号：US9095142B2

  公开（公告）日：2015-08-04